Ossifying fibromyxoid tumours: A case series
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115229 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Javier Pozas und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: javier.pozas@rmh.nhs.uk. Hauptthemen laut MEDLINE: Fibroma, Ossifying, Soft Tissue Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Ossifying fibromyxoid tumour is a rare mesenchymal soft tissue sarcoma with uncertain differentiation and variable metastatic potential. PATIENTS AND METHODS: This study offers a retrospective analysis of 23 patients diagnosed with OFMT between 1993 and 2024. RESULTS: The tumours most commonly arose in the extremities and trunk, with all patients undergoing surgical resection of the primary tumour. Immunohistochemical analysis frequently revealed the expression of S100 protein and desmin, while next-generation sequencing identified PHF1 rearrangements in 83 % of patients with available NGS, notably PHF1::EP400 and PHF1::TFE3 fusions. Five patients experienced local recurrence, and four developed metastatic disease. There is no prospective data to guide decision making with regards to systemic therapy, and doxorubicin-based regimens demonstrate limited efficacy. However, the potential role of epigenetic dysregulation in OFMT tumorigenesis opens exciting avenues for treatment. In this cohort, one patient exhibited a remarkably durable response to a combination of gemcitabine, which inhibits DNA methylation, and dacarbazine, following rapid tumour progression on doxorubicin. CONCLUSIONS: Given the limited clinical experience with OFMT, multidisciplinary tumour boards are crucial for tailoring individualized treatment strategies. This study contributes to the growing body of literature on OFMT, providing a foundation for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: javier.pozas@rmh.nhs.uk.
- Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: khin.thway@rmh.nhs.uk.
- Department of Pathology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Daniel.Lindsay@rmh.nhs.uk.
- Department of Cellular Pathology, Queen Elizabeth Hospital, Birmingham, UK. Electronic address: cyril.fisher@nhs.net.
- Department of Surgical Oncology, The Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK. Electronic address: myles.smithPA@rmh.nhs.uk.
- Department of Surgical Oncology, The Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK. Electronic address: Andrew.Hayes@rmh.nhs.uk.
Zitieren
APA
Pozas, J., Thway, K., Lindsay, D., Fisher, C., Smith, M., Hayes, A., Miah, A., Zaidi, S., Benson, C., Napolitano, A., Huang, P., & Jones, R. L. (2025). Ossifying fibromyxoid tumours: A case series. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115229
Vancouver
Pozas J, Thway K, Lindsay D, Fisher C, Smith M, Hayes A, et al. Ossifying fibromyxoid tumours: A case series. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115229
BibTeX
@article{Pozas2025,
author = {Pozas, Javier and Thway, Khin and Lindsay, Daniel and Fisher, Cyril and Smith, Myles and Hayes, Andrew and Miah, Aisha and Zaidi, Shane and Benson, Charlotte and Napolitano, Andrea and Huang, Paul and Jones, Robin L},
title = {Ossifying fibromyxoid tumours: A case series},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115229}
}
EUVIMED